GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome

[GlobeNewswire] – LONDON — GW Pharmaceuticals plc (AIM:GWP) (GW) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex(R), GW’s product candidate … more

View todays social media effects on GWPH

View the latest stocks trending across Twitter. Click to view dashboard

See who GW is hiring next, click here to view

Share this post